Jim Reddoch

JIM REDDOCH is a Healthcare Senior Analyst at Friedman, Billings, Ramsey
Group, Inc., and follows companies that are developing new, cutting-edge
therapies for diseases such as cancer, rheumatoid arthritis, psoriasis,
AIDS, and hepatitis C. Dr. Reddoch joined FBR in May 2003, after five
years of covering the biotech industry, most recently at Banc of America
Securities. As a Senior Analyst, he was known for his new methodologies
for valuing the early-stage products of young companies, his concerns
about the valuations of some genomics companies, as well as his ability
to identify and rank upcoming, stock-moving events in the biotech space.
Prior to venturing into finance, Dr. Reddoch was a postdoctoral fellow
at Yale University School of Medicine in the department of Therapeutic
Radiology, where his project focused on the relationship between genetic
mutations and cancer. During his time at Yale, Dr. Reddoch also served
as a consultant for the school’s technology transfer arm. He received
his PhD in biochemistry and molecular genetics from the University of
Alabama Medical School, where he founded the Industry Roundtable, now in
its eighth year ‘ which features speakers in finance, law, and health
care. Dr. Reddoch’s undergraduate degree, from Furman University, is in
Political Science.